Aclaris Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.97 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 615.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Details
| Name | Aclaris Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 73 |
| Founded | 2012 |
| Ipo Date | 2015-10-07 |
| Ceo | Neal Walker |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US00461U1051 |
| Cusip | 00461U105 |
| Cik | 0001557746 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Neal S. Walker D.O., M.D. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Hugh M. Davis Ph.D. | President, Chief Operating Officer and Director |
| Kevin Balthaser | Chief Financial Officer |
| James Loerop | Chief Business Officer |
| Dr. Roland Kolbeck Ph.D. | Chief Scientific Officer |
| William C. Roberts | Senior Vice President of Corporate Communications and Investor Relations |
| Matthew Rothman J.D. | General Counsel and Corporate Secretary |
| Steve Tucker | Executive Vice President of Project Leadership |
| Dr. Jesse W. Hall M.D. | Chief Medical Officer |
| Nina Samra M.S. | Senior Vice President of Clinical Operations |
Contact
| Address | 701 Lee Road, Suite 103, Wayne, Pennsylvania 19087, United States |
| Phone | 484 324 7933 |
| Website | https://www.aclaristx.com |